Department of Urology, Academic Medical Center, University of Amsterdam, The Netherlands.

Developments in the technology applied to the field of minimally invasive surgery have led to the exploration of high-intensity focused ultrasound (HIFU) for the treatment of localized prostate cancer. Extensive research and continuous evolution have resulted in two commercially available HIFU devices: the Ablatherm((R)) and the Sonablate500((R)). These devices are conceptually the same; however, specific technical differences exist. This paper reviews the clinical outcomes obtained with these devices, evaluates the quality of the evidence from the individual trials, and provides the results of a head-to-head comparison in terms of oncologic outcomes and complication rates.

Written by
Tsakiris P, Thüroff S, de la Rosette J, Chaussy C.

Reference
J Endourol. 2008 Jan 22. Epub ahead of print.
doi:10.1089/end.2007.9849

PubMed Abstract
PMID:18211209

UroToday.com HIFU Resource Center

Please log-in or register in order to submit comments.

Powered by AkoComment!